Healthcare Industry News: metabolic disease
News Release - January 7, 2009
Daiichi Sankyo, Inc. Establishes Subsidiary in Puerto RicoNew office will provide marketing support to improve awareness and knowledge of Daiichi Sankyo's innovative treatments
PARSIPPANY, N.J., Jan. 7 -- (Healthcare Sales & Marketing Network) -- Daiichi Sankyo, Inc., announced today that it has established a subsidiary -- Daiichi Sankyo de Puerto Rico, Inc. Daiichi Sankyo de Puerto Rico, Inc. is based in San Juan, and led by Jose Vazquez, Regional Director -- Puerto Rico, who has more than 20 years of experience in pharmaceutical sales and marketing. Vazquez, who earned his Bachelor of Arts degree in Biology and Juris Doctor from the University of Puerto Rico, has assembled an experienced team of sales representatives and marketing professionals with many years of experience and deep knowledge of the local market in Puerto Rico.
"We are excited about the opening of this new office in Puerto Rico. Our presence here enables us to establish close ties with healthcare partners throughout Puerto Rico and to directly support our customers with educational materials and managed care programs," said Vazquez. "The opening of this office is another indication of the growth of Daiichi Sankyo, which is fueled by our expanding portfolio of marketed products, as well as by our robust pipeline of promising new compounds. The new office in San Juan will ensure that our Puerto Rico customers have direct access to information about these innovative products."
Daiichi Sankyo de Puerto Rico, Inc., as a sales agent for Daiichi Sankyo, Inc. in Puerto Rico, will provide the local medical community and their patients direct access to materials and information about Daiichi Sankyo, Inc.'s products that address medical needs in cardiovascular and diabetes care. Daiichi Sankyo's current portfolio of marketed products is focused on hypertension, cholesterol and type 2 diabetes. The current focus of Daiichi Sankyo's research and development is cardiovascular and metabolic disease, including therapies for dyslipidemia, hypertension, diabetes and acute coronary syndrome. Daiichi Sankyo is also pursuing the discovery of new medicines in the areas of thrombosis, cancer, diabetes, and autoimmune disease/rheumatoid arthritis.
The new Daiichi Sankyo de Puerto Rico, Inc. office is located at The Atrium Office Center, 530 Avenida de la Constitucion, Office Number 258, Puerta de Tierra, San Juan, Puerto Rico 00901-2304. The office's main telephone number is 787-289-8700.
About Daiichi Sankyo
A global pharma innovator, Daiichi Sankyo Co., Ltd., was established in 2005 through the merger of two leading Japanese pharmaceutical companies. This integration created a more robust organization that allows for continuous development of novel drugs that enrich the quality of life for patients around the world. A central focus of Daiichi Sankyo's research and development are thrombotic disorders, malignant neoplasm, diabetes mellitus, and autoimmune disorders. Equally important to the company are hypertension, hyperlipidemia or atherosclerosis and bacterial infections. For more information, visit http://www.daiichisankyo.com/.
Daiichi Sankyo, Inc., headquartered in Parsippany, New Jersey, is the U.S. subsidiary of Daiichi Sankyo Co., Ltd. For more information on Daiichi Sankyo, Inc., please visit http://www.dsus.com/.
Source: Daiichi Sankyo
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsDaiichi Sankyo, Inc. Appoints Simon King as Chief People Officer across U.S. Divisions
Results of the Pivotal Phase 3 Study of the Bempedoic Acid / Ezetimibe Combination Tablet Published in the European Journal of Preventative Cardiology Demonstrated Significant LDL-C Lowering
Daiichi Sankyo Provides Update on FDA Review of Quizartinib for the Treatment of Patients with Relapsed/Refractory FLT3-ITD AML